Trial Profile
A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 09 Oct 2023 Status changed from recruiting to discontinued.
- 31 Mar 2017 New trial record